摘要
目的探讨普罗布考、瑞舒伐他汀单用及合用对高血压病患者动脉粥样硬化及心功能的影响。方法入选门诊高血压病患者178例,随机分为瑞舒伐他汀治疗组(10 mg/d,睡前)、普罗布考治疗组(500 mg/d)和瑞舒伐他汀与普罗布考联合治疗组,治疗随防8个月。治疗前后行超声心动图、核素心血池检查和血清肿瘤坏死因子α、基质金属蛋白酶等检查。结果治疗8个月后,三个治疗组与治疗前比较,总胆固醇、低密度脂蛋白胆固醇、颈动脉内膜中膜厚度和冠状动脉钙化积分均明显降低,血清肿瘤坏死因子α、基质金属蛋白酶2和基质金属蛋白酶9均明显减少;尤以联合治疗组较甚(P<0.01)。联合治疗组治疗后左心室射血分数和左心室高峰充盈率明显增加。结论普罗布考与瑞舒伐他汀合用,可进一步缓解高血压病患者的动脉粥样硬化和改善其心功能,其机制可能与降低血清肿瘤坏死因子α及基质金属蛋白酶有关。
Ahn To explore the effect of probucol, rosuvastatin and their combination on atheroselerosis and cardiac function in essential hypertensive patients. Methods A total of 178 essential hypertensive patients ,were randomly assigned to rosuvastatin group （ rosuvastatin, 10 mg/d ）, probucol group （ probucol, 500 mg/d ） and the combination group （ rosuvastatin ＋ probueol ）. All the patients were treated and followed up for 8 months. The changes of matrix metalloproteinase （MMP）, tumor necrosis factor （TNF-α） , atherosclerosis plaque of artery and cardiac function between baseline and the end of 8 months were analysed. Results At the end of 8 months, rosuvastatin group, prohueol group and the combination group showed reductions in MMP, TNF-α, the intima media thickness （ IMT） of the common carotid artery and the size of plaque in coronary artery （ CS ） ; and the combination group showed more reductions compared with rosuvastatin group and probueol group. Left ventrieular ejection fraction（LVEF） increased from 60.2%± 11.0% to 64.4% ± 12.5% （ P 〈 0.05 ） and left ventricular peak filling rate （ LVPFR ） increased from 1.78 ± 0.39 to 2.89 ± 0.67 （ P 〈 0. 01 ） in the combination group. Conclusion The combined treatment with probueol and rosuvastatin yielded better results in the context of improving left ventrieular function and showed favorable effects on atheroselerosis plaque of artery.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2009年第6期481-483,490,共4页
Chinese Journal of Arteriosclerosis
